TY - JOUR
T1 - Cancer screening in China
T2 - a steep road from evidence to implementation
AU - Xia, Changfa
AU - Basu, Partha
AU - Kramer, Barnett S.
AU - Li, He
AU - Qu, Chunfeng
AU - Yu, Xue Qin
AU - Canfell, Karen
AU - Qiao, Youlin
AU - Armstrong, Bruce K.
AU - Chen, Wanqing
N1 - Funding Information:
We acknowledge funding from the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (number 2021-I2M-1-033), the National Natural Science Foundation of China (no 82273721), and the Sanming Project of the Medicine in Shenzhen (no SZSM201911015). The authors alone are responsible for the views expressed in this Review and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. Where authors are identified as personnel of the International Agency for Research on Cancer/WHO, the authors alone are responsible for the views expressed in this Review and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/WHO. The Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations with respect to territorial claims in published figures.
Publisher Copyright:
© 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license
PY - 2023/12
Y1 - 2023/12
N2 - Cancer screening has the potential to decrease mortality from several common cancer types. The first cancer screening programme in China was initiated in 1958 and the Cancer High Incidence Fields established in the 1970s have provided an extensive source of information for national cancer screening programmes. From 2012 onwards, four ongoing national cancer screening programmes have targeted eight cancer types: cervical, breast, colorectal, lung, oesophageal, stomach, liver, and nasopharyngeal cancers. By synthesising evidence from pilot screening programmes and population-based studies for various screening tests, China has developed a series of cancer screening guidelines. Nevertheless, challenges remain for the implementation of a fully successful population-based programme. The aim of this Review is to highlight the key milestones and the current status of cancer screening in China, describe what has been achieved to date, and identify the barriers in transitioning from evidence to implementation. We also make a set of implementation recommendations on the basis of the Chinese experience, which might be useful in the establishment of cancer screening programmes in other countries.
AB - Cancer screening has the potential to decrease mortality from several common cancer types. The first cancer screening programme in China was initiated in 1958 and the Cancer High Incidence Fields established in the 1970s have provided an extensive source of information for national cancer screening programmes. From 2012 onwards, four ongoing national cancer screening programmes have targeted eight cancer types: cervical, breast, colorectal, lung, oesophageal, stomach, liver, and nasopharyngeal cancers. By synthesising evidence from pilot screening programmes and population-based studies for various screening tests, China has developed a series of cancer screening guidelines. Nevertheless, challenges remain for the implementation of a fully successful population-based programme. The aim of this Review is to highlight the key milestones and the current status of cancer screening in China, describe what has been achieved to date, and identify the barriers in transitioning from evidence to implementation. We also make a set of implementation recommendations on the basis of the Chinese experience, which might be useful in the establishment of cancer screening programmes in other countries.
UR - http://www.scopus.com/inward/record.url?scp=85177765230&partnerID=8YFLogxK
U2 - 10.1016/S2468-2667(23)00186-X
DO - 10.1016/S2468-2667(23)00186-X
M3 - Review article
C2 - 38000379
AN - SCOPUS:85177765230
SN - 2468-2667
VL - 8
SP - e996-e1005
JO - The Lancet Public Health
JF - The Lancet Public Health
IS - 12
ER -